Genedrive Share News (GDR)

EARNINGS AND TRADING: Fenikso in profit; Tate & Lyle completes sale

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

LONDON MARKET CLOSE: FTSE 100 stumbles as rain dampens retail sales

(Alliance News) - Stock prices in London closed mixed on Friday, with the FTSE 100 finishing lower, but smaller indices ending in the green.

UK shareholder meetings calendar - next 7 days

Genedrive test ordered by five Manchester area hospitals

(Sharecast News) - Point-of-care pharmacogenetic testing company Genedrive announced on Friday that it has received initial orders for its Genedrive MT-RNR1 products from five additional UK hospitals in the Greater Manchester area.

LONDON MARKET MIDDAY: FTSE 100 in red as UK election heats up

(Alliance News) - Stock prices in London were mostly in the red at midday Friday, as the UK election debate heats up and retail sales come in below expectations.

Genedrive announces orders for testing kit worth over GBP100,000

(Alliance News) - Genedrive PLC on Friday said it had received initial UK orders for its MT-RNR1 testing kit.

AIM WINNERS & LOSERS: Kinovo rises as results ahead of expectations

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

TRADING UPDATES: CVS sells Dutch and Irish loss-making businesses

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

IN BRIEF: Genedrive completes placing portion of GBP6 million raise

Genedrive PLC - Manchester-based pharmacogenetic testing - Completes placing of 138.8 million new shares at 1.5 pence each, raising GBP2.1 million. The placing is part of an overall equity raise being run by Peel Hunt LLP. Late Thursday, Genedrive had said it will try to raise a minimum of GBP6.0 million, including offers to retail investors. If that minimum is not reached, then only the firm placing will go ahead. The placing and retail offer prices will be the same and represent a more than 50% discount to Genedrive's closing price on Thursday. The placing shares will almost double Genedrive's total, and the retail offers could see another 376.4 million new shares issued. It expects to call a general meeting for May 31 to approve the share issue.

AIM WINNERS & LOSERS: Polarean wins deal; Genedrive completes placing

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

IN BRIEF: Genedrive aims to raise at least GBP6 million in share offer

Genedrive PLC - Manchester-based pharmacogenetic testing company - Seeks to raise a minimum of GBP6.0 million from an offer of new shares at 1.5 pence each. The announcement is made after the London market close on Thursday, and the price represents a more than 50% discount to Genedrive's closing price. The equity raise will be split into a firm placing of shares for GBP2.5 million, an offer to new and existing retail investors via the REX platform for GBP3.5 million, and an open offer to existing shareholders for GBP2.1 million. Genedrive says that if the GBP6.0 million minimum target is not reached, then only the firm placing will go ahead. The share sale is being run by broker Peel Hunt LLP.

Genedrive enters clinical trial deal in US for MT-RNR1 US approval

(Alliance News) - Genedrive PLC on Wednesday said it has entered into a clinical trial agreement to support clinical studies to progress the regulatory approval of its MT-RNR1 product.

LONDON MARKET CLOSE: FTSE 100 up thanks to US economic data

(Alliance News) - Stock prices in London closed mostly higher on Wednesday, after some data from the US reinforced the interest rate cut trajectory across the Atlantic.

Genedrive shares jump on NICE test recommendation

(Sharecast News) - Genedrive shares were surging on Wednesday, after it received a significant endorsement from the UK's National Institute for Health and Care Excellence (NICE) regarding its 'CYP2C19-ID' test.

Genedrive shares surge as UK's NICE backs test for ischaemic stroke

(Alliance News) - Genedrive PLC on Wednesday praised the National Health Service's work on strokes and mini strokes as a test by the company received a recommendation from the UK's National Institute for Health & Care Excellence.